https://www.selleckchem.com/products/pfk15.html
Median follow-up was for an uninterrupted period of 937days (139-1375days), which did not vary significantly among the genotypes. The MAF was 47% in ASD patients vs. 51% in a local reference population with similar ethnic background; the clinical severity and progression were not affected by the minor allele. Carriers of the minor allele exhibited higher adaptive behavior in the domains "daily living skills" and "communication", which correlated positively with the dose of the minor allele. The MAF is not different in ASD children, but ca
Curtir
Comentario
Compartilhar
